Department of Neurology, Juntendo Tokyo Koto Geriatric Medical Center, 3-3-20 Shinsuna, Koto, Tokyo 136-0075, Japan.
Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.
Alpha-synuclein is a major component of Lewy bodies and glial cytoplasmic inclusions, pathological hallmarks of idiopathic Parkinson's disease and multiple system atrophy, and it is assumed to be aetiologically involved in these conditions. However, the quantitative status of brain alpha-synuclein in different Parkinsonian disorders is still unresolved and it is uncertain whether alpha-synuclein accumulation is restricted to regions of pathology. We compared membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein, both the full-length 17 kDa and high molecular weight species, by western blotting in autopsied brain of patients with Parkinson's disease (brainstem-predominant Lewy body disease: n = 9), multiple system atrophy (n = 11), progressive supranuclear palsy (n = 16), and of normal controls (n = 13). Brain of a patient with familial Parkinsonism-dementia due to alpha-synuclein locus triplication (as positive control) showed increased membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein levels with abundant high molecular weight immunoreactivity. In multiple system atrophy, a massive increase in 17 kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein was observed in highly pathologically affected regions, including putamen (+1760%, range +625-2900%), substantia nigra [+1000% (+356-1850%)], and white matter of internal capsule [+2210% (+430-6830%)] together with numerous high molecular weight species. Levels of 17 kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein were only modestly increased in less affected areas (cerebellar cortex, +95%; caudate, +30%; with both also showing numerous high molecular weight species) and were generally normal in cerebral cortices. In both Parkinson's disease and progressive supranuclear palsy, membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein levels were normal in putamen and frontal cortex whereas a trend was observed for variably increased 17 kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein concentrations [+184% (-60% to +618%)] with additional high molecular weight species in Parkinson's disease substantia nigra. No obvious correlation was observed between nigral membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein accumulation and Lewy body density in Parkinson's disease. Two progressive supranuclear palsy cases had membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein accumulation in substantia nigra similar to multiple system atrophy. Several Parkinson's disease patients had very modest high molecular weight membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein accumulation in putamen. Levels of 17-kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein were generally positively correlated with those of high molecular weight membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein and there was a trend for a positive correlation between striatal dopamine loss and 17-kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein concentrations in multiple system atrophy. Brain membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein accumulations in Parkinson's disease and multiple system atrophy are regionally specific, suggesting that these sporadic alpha-synucleinopathies, unlike familial Parkinsonism-dementia, are not associated with a simple global over-expression of the protein. Despite a similar extent of dopamine depletion, the magnitude of brain membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein changes is disease specific, with multiple system atrophy clearly having the most severe accumulation. Literature discrepancies on alpha-synuclein status in 'Parkinson's disease' might be explained by inclusion of cases not having classic brainstem-predominant Lewy body disease and by variable alpha-synuclein accumulation within this diagnostic classification.
α-突触核蛋白是路易体和神经胶质细胞质包含物的主要成分,是特发性帕金森病和多系统萎缩的病理标志物,并且假定在这些疾病中具有病因学上的参与。然而,不同帕金森病患者脑中的α-突触核蛋白的定量状况仍未解决,并且不确定α-突触核蛋白的积累是否仅限于病变区域。我们通过免疫印迹法比较了尸检大脑中膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白,包括全长 17 kDa 和高分子量的物质,这些样本来自于帕金森病患者(脑干为主的路易体病:n = 9)、多系统萎缩患者(n = 11)、进行性核上性麻痹患者(n = 16)和正常对照组(n = 13)。由于α-突触核蛋白基因三倍体引起的家族性帕金森病-痴呆症患者的大脑(作为阳性对照)显示膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白水平增加,并且存在丰富的高分子量免疫反应。在多系统萎缩中,在高度病理受影响的区域(包括壳核[+1760%(范围:+625-2900%)]、黑质[+1000%(+356-1850%)]和内囊的白质[+2210%(+430-6830%)])中观察到 17 kDa 膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白的大量增加,同时还有许多高分子量物质。在受影响较小的区域(小脑皮质[+95%]和尾状核[+30%])中,17 kDa 膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白的水平仅适度增加,并且在大脑皮质中通常正常。在帕金森病和进行性核上性麻痹中,壳核和额叶皮质中的膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白水平正常,而帕金森病黑质中观察到 17 kDa 膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白浓度呈递增趋势[+184%(-60%至+618%)],同时伴有额外的高分子量物质。在帕金森病中,黑质中膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白的积累与路易体密度之间没有明显的相关性。两个进行性核上性麻痹病例的黑质中存在类似于多系统萎缩的膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白积累。一些帕金森病患者的壳核中仅有非常轻微的高分子量膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白积累。17 kDa 膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白的水平通常与高分子量膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白的水平呈正相关,并且在多系统萎缩中存在纹状体多巴胺丢失与 17 kDa 膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白浓度之间的正相关趋势。帕金森病和多系统萎缩中大脑膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白的积累是区域性的,表明这些散发性的α-突触核蛋白病,与家族性帕金森病-痴呆症不同,与蛋白质的简单整体过度表达无关。尽管多巴胺的耗竭程度相似,但大脑膜相关的、十二烷基硫酸钠可溶的α-突触核蛋白变化的程度是疾病特异性的,多系统萎缩显然具有最严重的积累。关于“帕金森病”中α-突触核蛋白状态的文献差异可能是由于包括了不具有经典脑干为主的路易体病的病例,以及在这个诊断分类中α-突触核蛋白的积累程度不同。